7 September 2018, San
Francisco: The global erythropoietin
(EPO) drugs market is expected to reach USD 17.4 billion by 2025,
according to a new report by Grand View Research, Inc. Rising incidence of
chronic diseases such as CKD and cancer resulting in anemia is a major growth
driver of this market.
According to the statistics published by
the National Heart, Lung, and Blood Institute of the U.S. Department of Health
& Human Services, over 3 million people are affected by anemia every year
and this number is expected to increase over the forecast period. This
showcases the need for erythropoietin-stimulating agents in the coming years.
Introduction of novel drugs and their
cheaper biosimilar formulations with enhanced efficacy and cost-effectiveness
is also expected to serve this industry with lucrative opportunities. For
instance, development of numerous biosimilars in the European market is
expected to gain traction and increase their usage rates, owing to associated
benefits such as less time required for approval, cost-efficiency, and enhanced
therapeutic effect.
Companies are involved in extensive R&D
initiatives for development of innovative molecules and discovering new
therapeutic areas for existing drugs. For instance, in April 2016, Sandoz
received approval from the European Commission for use of its biosimilar
Binocrit in nephrology indications, thereby extending the therapeutic area of
its product portfolio.
Moreover, many of the industry players in
the U.S., Europe, and Asia Pacific are involved in the development of new
biosimilars. For example, Biocon’s subsidiary Syngene International entered
into an agreement with Bristol-Myers Squibb to extend their drug discovery and
development program in India. This enables Biocon to enhance its erythropoietin
drugs portfolio. Expected product approvals in the coming years are anticipated
to fuel market growth.
Access Research Report
of Erythropoietin Drug Market@ www.grandviewresearch.com/industry-analysis/erythropoietin-epo-drugs-market
Further key findings from the study suggest:
· The biologics segment is declining over the
forecast period owing to patent expiration of branded biologics and introduction
of biosimilars in the market
· The patent for Aranesp (darbepoetin-alfa)
will expire in 2024 in the U.S. and is expected to provide numerous future
growth opportunities for new market entrants
· Epoetin-alfa held the largest share of
product segment owing to its early introduction in the U.S. market and patent
protection
· Epoetin-omega and epoetin-zeta are
anticipated to exhibit lucrative growth over the forecast period owing to
associated benefits such as longer half-life and enhanced therapeutic effects
· Use of erythropoietin drugs for treatment
of renal diseases held a dominant share as of 2016 owing to the increasing
incidence of chronic kidney diseases
· The Asia Pacific regional industry for
erythropoietin-stimulating agents is expected to witness lucrative CAGR during
the forecast period
· Industry participants are focusing on the
discovery of new therapeutic areas for existing drugs and development of
cost-effective biosimilars, thereby increasing R&D activities for the
development of erythropoietin drugs.
Browse more reports of this category by Grand View
Research at: www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has segmented the
erythropoietin (EPO) drugs market on the basis of the drug class, product,
application, and region:
Erythropoietin Drugs Drug class Outlook
(Revenue, USD Million, 2014 - 2025)
·
Biologics
·
Biosimilar
Erythropoietin Drugs Product Outlook
(Revenue, USD Million, 2014 - 2025)
·
Epoetin-alfa
·
Epoetin-beta
·
Darbepoetin-alfa
·
Others
Erythropoietin Drugs Application Outlook
(Revenue, USD Million, 2014 - 2025)
·
Cancer
·
Hematology
·
Renal Diseases
·
Neurology
Erythropoietin Drugs Regional Outlook
(Revenue, USD Million, 2014 - 2025)
·
North America
o
U.S.
o
Canada
·
Europe
o
Germany
o
UK
·
Asia Pacific
o
Japan
o
China
o
India
·
Latin America
o
Brazil
o
Mexico
·
MEA
o
South Africa
Access Press Release of
Erythropoietin Drug Market@: www.grandviewresearch.com/press-release/global-erythropoietin-epo-drugs-market
About
Grand View Research
Grand View Research, Inc. is a
U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides
syndicated research reports,
customized research reports, and consulting services. To help clients make
informed business decisions, we offer
market intelligence studies ensuring relevant and fact-based research across a
range of industries, from technology to chemicals, materials and healthcare.
